Importance and pathogenesis of abnormal movements during L-dopa therapy of Parkinson's disease.
D000284:Administration, Oral; D000818:Animals; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects*; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D009069:Movement Disorders / Q000139:chemically induced*; D009129:Muscle Tonus / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy; D051381:Rats; D012026:Reflex, Stretch; D014439:Tyramine / Q000494:pharmacology
D004295:Dihydroxyphenylalanine; D006220:Haloperidol; D014439:Tyramine